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To assess the prognostic factors in patients with transitional-cell carcinoma of the renal pelvis and/or
ureter, a series of 138 patients with transitional-cell carcinoma of the renal pelvis and/or ureter was
collected in a retrospective multicentre study. 12 patients with distant metastases were excluded from
the statistical evaluation. All but 3 patients underwent radical surgery: nephroureterectomy (n = 71),
nephroureterectomy and lymphadenectomy (n = 20), nephroureterectomy and partial bladder resec-
tion or transurethral resection (n = 20), nephrectomy (n = 10), and ureterectomy (n = 5). Sixty-one per
cent (n = 77) of the tumours were located in the renal pelvis, and 21% (n = 27) in the ureter (both in 22
[17%]). Following surgery, residual tumour was still present in 33 patients (16 microscopic and 17
macroscopic). Postoperative radiotherapy was given to 45 (36%) patients. The median follow-up period
was 39 months. In a median period of 9 months, 66% of the patients relapsed (34 local, 7 locoregional, 16
regional, and 24 distant). The 5- and 10-year survival were 29% and 19%, respectively, in all patients.
In univariate analyses, statistically signi®cant factors in¯uencing the outcome were Karnofsky index,
pT-classi®cation, pN-classi®cation, tumour localisation, grade, and residual tumour after surgery.
Multivariate analysis revealed that independent prognostic factors in¯uencing outcome were pT-
classi®cation, the existence of residual tumour, and tumour localisation. In patients with urothelial
renal pelvis and/or ureter tumours, a radical surgical attitude is mandatory; and the presence of tumour
in the ureter is associated with a poorer prognosis. # 1999 Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Transitional-cell carcinoma of the renal pelvis and the
ureter is a relatively rare cancer [1]. Its treatment is primarily
surgical varying from conservative surgery to more extensive
surgical procedures, i.e., radical nephroureterectomy includ-
ing the removal of the contents of Gerota's fascia with ipsi-
lateral ureter and a cuV of bladder at its distal extent [2].
The role of adjuvant radiation therapy is not well estab-
lished. In circumstances in which conservative resection is
performed, postoperative radiation therapy is considered. A
bene®cial eVect has been suggested by some [3±6] but ques-
tioned by others [7]. In this multicentre study, combining the
experience of eight European institutions, the aims were to
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assess the prognostic factors, the extent of surgery, the role of
adjuvant postoperative radiation therapy, and the outcome in
patients with transitional-cell carcinoma of the renal pelvis
and/or ureter.
PATIENTS AND METHODS
A series of 138 patients with transitional-cell carcinoma of
the renal pelvis and/or ureter treated between 1971 and 1996
was collected in a retrospective multicentre study of the Rare
Cancer Network. 12 patients with distant metastases were
excluded from the statistical evaluation. In the remaining 126
patients, the median age was 66 years (range: 41±87). The
male to female ratio was 2.5 (90:36). The median follow-up
period was 39 months (range: 5±220).
Information concerning the performance status according
to the Karnofsky index was available for 65 (52%) patients. It
was < 80% in 14 patients, 80% in 17, 90% in 17, and 100%
in 17. The most frequently occurring symptom was haema-
turia alone (n = 55) or combined with back pain (n = 31),
back pain alone (n = 12) or combined with other symptoms
(n = 2), urinary infections (n = 4), weight loss (n = 3), and
hypertension in 1 patient. 18 patients presented initially
without any clinical symptom.
The surgical treatment was nephroureterectomy (n = 71),
nephroureterectomy and lymph node dissection (n = 20),
nephroureterectomy and partial bladder resection or transur-
ethral resection (n = 20), nephrectomy alone (n = 10), and
ureterectomy (n = 5).
According to the UICC classi®cation [8] there were 6
(5%) pTa (papillary non-invasive carcinoma), 22 (17%) pT1
(invasion of subepithelial connective tissue), 17 (14%) pT2
(invasion of the muscularis), 37 (29%) pT3 (invasion beyond
the muscularis into peripelvic fat or renal parenchyma for
renal pelvis tumours, or into the periureteric fat for ureter
tumours), 37 (29%) pT4 (invasion of adjacent organs or
through the kidney into perinephric fat), and 7 (6%) pTX
(primary tumour cannot be assessed) tumours. The pN-clas-
si®cation was as follows: 69 (55%) pN0 (no regional lymph
node metastasis), 8 (6%) pN1 (metastasis in a single lymph
node  2 cm), 14 (11%) pN2 (metastasis in a single lymph
node > 2 but  5 cm, or multiple lymph nodes < 5 cm), 4
(3%) pN3 (metastasis in a lymph node > 5 cm), and 31
(25%) pNX (regional lymph nodes cannot be assessed).
Sixty-one per cent (n = 77) of the tumours were located in the
renal pelvis, and 21% (n = 27) in the ureter. Renal pelvis and
ureter localisation were present together in 22 (17%)
patients. There were 4 (3%) grade 1, 37 (29%) grade 2, 42
(33%) grade 3 tumours; and the grade was not registered in
43 (34%) patients. Following surgery, microscopic (n = 16)
or macroscopic (n = 17) residual tumour was detected in 26%
of the patients. The characteristics of the patients according
to diVerent treatment modalities are presented in Table 1.
Postoperative radiotherapy was given using anterior±pos-
terior portals in 45 (36%) patients with a median total dose of
50 Gy (range: 20±66) in median 25 fractions (range: 4±33).
The postoperative target volume was mostly the kidney and
the ureteral bed in 27 patients, or the same volume including
the bladder (n = 10). Patients receiving postoperative radia-
tion had signi®cantly higher pT classi®cation, ureteral locali-
sation, and higher grade tumours after surgery compared with
non-irradiated patients (P < 0.0001, P = 0.02, and P = 0.06;
respectively) (Table 1). Adjuvant systemic chemotherapy was
administered in 12 (10%) patients.
Means were compared by Student's t-test. Proportions
were compared using the chi-square test for values greater
than 5, and Fisher's exact test for those less than or equal to
5. Kaplan±Meier product-limit estimates were used to evalu-
ate the survival, local control, and locoregional control [9].
The events were death (all causes of death included) for
overall survival, and local or locoregional relapse for local and
locoregional control (patients who died without local or
locoregional relapse were censored at time of death), respec-
tively. DiVerences between groups were assessed using the
logrank test [10]. Bonferroni method was used to adjust the
individual P-values in order to obtain overall signi®cance
levels depending on the number of parameters tested
(P-adjusted equals individual P-value times number of
parameters tested) [11]. Multivariate analyses were done
Table 1. Characteristics of 126 patients with urothelial renal







Mean  S.D. age (years) 66  11 65  9 0.47
Sex
Female 21 (26) 15 (33) 0.38
Male 60 (74) 30 (67)
Karnofsky index
 80% 33 (41) 18 (40) 0.32
< 80% 7 (8) 7 (16)
Unknown 41 (51) 20 (44)
Tumour localisation
Renal pelvis 57 (70) 20 (45) 0.02
Ureter 13 (16) 14 (31)
Both 11 (14) 11 (24)
Type of surgery
Nephroureterectomy (NU) 46 (57) 25 (56) 0.46
NU + lymphadenectomy (L) 14 (17) 6 (13)
Nephrectomy + partial bladder
resection (or TURB)
13 (16) 7 (15)
Nephrectomy alone 6 (7) 4 (9)
Ureterectomy alone 2 (3) 3 (7)
pT-classi®cation
pTa 6 (7) ± < 0.0001
pT1 21 (26) 1 (2)
pT2 13 (16) 4 (9)
pT3 21 (26) 16 (36)
pT4 14 (18) 23 (51)
pTX 6 (7) 1 (2)
pN-classi®cation
pN0 45 (56) 24 (53) 0.14
pN1 4 (5) 4 (9)
pN2 7 (9) 7 (16)
pN3 1 (1) 3 (7)
pNX 24 (29) 7 (15)
Grade
1 4 (5) ± 0.06
2 28 (34) 9 (20)
3 25 (31) 17 (38)
Unknown 24 (30) 19 (42)
Residual tumour
None 63 (78) 30 (67) 0.10
Microscopic 11 (14) 5 (11)
Macroscopic 7 (8) 10 (22)
RT, radiation therapy; TURB, transurethral resection, bladder.
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using the Cox stepwise-regression analysis to determine the
independent contribution of each prognostic factor [12].
RESULTS
In a median period of 9 months (range: 1±141), 64%
(n = 81) of the patients relapsed (local in 34, locoregional in
7, regional in 16, and distant in 24). The distribution of
relapses is presented in detail in Table 2. The 5- and 10-year
overall survival ( S.D.) were 29  5% and 19  5%, respec-
tively in all patients. The 5- and 10-year local control rates
were 46  7% and 36  8%, and the locoregional control rates
were 37  5% and 29  7%, respectively (Figure 1).
In univariate analyses (Table 3), statistically signi®cant fac-
tors in¯uencing survival were pT-classi®cation (P < 0.00001;
P-adjusted < 0.0001), pN-classi®cation (P = 0.001; P-adjusted
< 0.01), tumour localisation (renal pelvis versus ureter  renal
pelvis; P = 0.003; P-adjusted < 0.05) (Figure 2), histological
grade (P < 0.00001; P-adjusted < 0.0001), and the existence
of residual tumour after surgery (P < 0.00001; P-adjus-
ted < 0.0001) (Figure 3). The only factor in¯uencing the
local or locoregional control probability was the presence or
not of a residual tumour following surgery (Table 4).
Table 2. Distribution of relapses (99 sites of relapse in 81 patients) according to treatment modality
Surgery alone (n = 81) Postoperative RT (n = 45)













Bladder 16 (27) 5 (38) 1 (13) 4 (13) 2 (29) ±
Renal 4 (7) 1 (8) 1 (13) 2 (6) ± 1 (14)
Ureter 1 (2) ± ± 2 (6) ± ±
Contralateral ureter ± 1 (8) ± 1 (3) ± ±
Regional
Paraaortic 11 (18) 3 (23) 1 (13) 3 (10) ± ±
Iliac 2 (3) ± ± ± 1 (14) ±
Inguinal ± ± ± ± 1 (14) ±
Distant
Liver 7 (12) 1 (8) 1 (13) 4 (13) 1 (14) ±
Bone 4 (7) ± 1 (13) 3 (10) ± ±
Lung 2 (3) ± ± ± ± 1 (14)
Skin ± ± ± 1 (3) ± ±
Brain ± ± ± 1 (3) ± ±
Adrenal gland ± ± ± ± ± 1 (14)
Supraclavicular 1 (2) ± ± ± ± ±
Bone + liver 1 (2) ± ± 2 (6) ± ±
Bone + lung 1 (2) ± ± ± ± ±
Lung + liver 1 (2) ± ± 1 (3) ± ±
RT, radiation therapy; NU  L, nephroureterectomy with or without lymphadenectomy; NUB, NU + partial bladder resection (or transure-
thral bladder resection); N/U, nephrectomy or ureterectomy alone.
Figure 1. 10-year projected probabilities of local control,
locoregional control and overall survival in 126 patients.
Figure 2. 10-year overall survival rates according to tumour
localisation: renal pelvis (n = 78) versus ureter  renal pelvis
(n = 48); P = 0.003; P-adjusted <0.05.
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Multivariate analysis (Table 5) revealed that independent
prognostic factors in¯uencing survival were pT-classi®cation
(Ta, T1, T2 versus T3, T4, TX; P < 0.00001), the existence
of residual tumour after surgery (no residual tumour versus
micro- or macroscopic rest; P < 0.00001), and tumour locali-
sation (renal pelvis versus ureter  renal pelvis; P = 0.007).
Residual tumour was found to be the only independent factor
for either local (P = 0.002) or locoregional (P = 0.0008)
control.
DISCUSSION
Tumours of the renal pelvis and ureter have a signi®cantly
high local recurrence rate after nephroureterectomy, particu-
larly in patients with high grade tumours or deep invasion
[13, 14]. The biology of these tumours is similar to transi-
tional-cell carcinoma of the bladder. The major prognostic
factors in patients with renal pelvis or ureter carcinoma are
initial stage, grade of the tumour, and extent of surgery [14±
17]. Clinical computed tomography (CT) staging may
enhance our ability to make a clinically relevant distinction
between minimally invasive and deeply invasive tumours thus
predicting the extent of surgery [18]. High grade tumours are
associated with a higher incidence of metastases and worse
survival [15]. No survival diVerence was found for patients
with papillary versus solid tumours [14]. Multifocal lesions
have a worse prognosis than the unifocal lesions at time of
initial diagnosis [15]. Flow cytometry, by determining the
DNA pattern (diploid versus aneuploid) has also been repor-
ted to be an important prognostic indicator for long-term
prognosis [15, 19].
In our series, among the factors analysed (Table 3) uni-
variate analyses revealed that the signi®cant factors in¯uen-
cing the survival were Karnofsky performance index, pT- and
pN-classi®cation, ureteral localisation, histological grade, and
existence of residual tumour after surgery. Independent
prognostic factors found to be signi®cant following multi-
variate analysis (Table 5) were pT-classi®cation, existence of
residual tumour, and ureteral localisation. Residual tumour
Table 3. Univariate analyses* in 126 patients (overall survival)
Overall survival (%)
n 5-yr. 10-yr. P-value Adjusted P-value**
All patients 126 29  5 19  5
Karnofsky index
80% 50 35  8 29  9 0.009 NS
<80% 13 12  10 ±
Tumour localisation
Renal pelvis 78 39  6 29  7 0.003 < 0.05
Ureter  renal pelvis 48 14  6 7  5
Type of surgery
Nephroureterectomy (NU)  lymphadenectomy 91 29  6 18  6 0.91 NS
NU + partial bladder resection (or TURB) 20 29  12 19  11
Nephrectomy or ureterectomy alone 15 23  14 23  14
pT-classi®cation
pTa 6 56  25 ± < 0.00001 < 0.0001
pT1 22 45  13 33  14
pT2 17 61  13 41  19
pT3 37 15  7 5  5
pT4 37 16  7 6  5
pTX 7 0 0
pN-classi®cation
pN0 69 32  6 25  6 0.001 < 0.01
pN1 8 25  15 ±
pN2 14 8  8 8  8
pN3 4 0 0
pNX 31 32  12 16  13
Grade
1 4 67  27 ± < 0.00001 < 0.0001
2 37 52  10 35  12
3 42 16  6 11  6
Unknown 43 17  6 14  6
Residual tumour
None 93 37  6 24  6 < 0.00001 < 0.0001
Microscopic 16 9  8 9  8
Macroscopic 17 0 0
Postoperative RT
No 81 33  6 24  6 0.04 NS
Yes 45 21  7 13  6
*Logrank test [10]; **Bonferroni correction [11]; NS, not signi®cant; TURB, transurethral resection, bladder; RT, radiation therapy.
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was the only signi®cant factor in either univariate (Table 4)
or multivariate analyses for either local or locoregional
control.
Few data support the routine use of adjuvant postoperative
radiation therapy in transitional-cell carcinoma of the renal
pelvis or ureter (Table 6). It may be helpful in selected cases
with high tumour stage, high tumour grade, and/or in
patients with lymph node metastases, and it remains an
unproven adjunct for the control of residual tumour. Using
postoperative radiation therapy, some retrospective series
suggest a decreased local relapse rate in patients with high
Table 4. Univariate analyses* in 126 patients (local and locoregional control)
n 5-yr. 10-yr. P-value Adjusted P-value**
Local control (%)
All patients 126 46  7 36  8
Tumour localisation
Renal pelvis 78 51  8 51  8 0.30 NS
Ureter  renal pelvis 48 35  12 18  11
Type of surgery
Nephroureterectomy (NU)  lymphadenectomy 91 47  8 35  10 0.80 NS
NU + partial bladder resection (or TURB) 20 35  14 35  14
Nephrectomy or ureterectomy alone 15 68  15 68  15
Residual tumour
No 93 50  8 38  10 0.0003 0.001
Yes 33 34  16 34  16
Postoperative RT
No 81 48  8 36  10 0.84 NS
Yes 45 39  13 39  13
Locoregional control (%)
All patients 126 37  5 29  7
Tumour localisation
Renal pelvis 78 44  7 44  7 0.20 NS
Ureter  renal pelvis 48 24  9 12  7
Type of surgery
Nephroureterectomy (NU)  lymphadenectomy 91 39  7 29  8 0.40 NS
NU + partial bladder resection (or TURB) 20 26  11 26  11
Nephrectomy or ureterectomy alone 15 57  16 57  16
Residual tumour
No 93 41  7 31  8 0.0002 < 0.001
Yes 33 27  13 27  13
Postoperative RT
No 81 38  7 29  8 0.92 NS
Yes 45 33  12 33  12
*Logrank test [10]; **Bonferroni correction [11]; NS, not signi®cant; TURB, transurethral resection, bladder; RT, radiation therapy.




pT-classi®cation (a, 1, 2 versus 3,
4, X)
5.96 (2.7±14.5) < 0.00001
Residual tumour (no versus yes) 8.33 (3.5±19.6) < 0.00001
Tumour localisation (renal pelvis
versus ureter  renal pelvis)
1.69 (1.2±2.5) 0.007






Grade (1, 2 versus 2, 3) 1.88 (0.7±5.9) 0.25
*Cox model [12].
Figure 3. 10-year overall survival rates according to residual
tumour following surgery: no residual tumour (n=93), micro-
scopic (n=16), and macroscopic (n=17); P<0.00001; P-adjus-
ted<0.0001.
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stage and/or high grade tumours with or without positive
lymph nodes [3±6]. Others did not observe any advantage of
adjuvant radiation therapy [7].
In this multicentre retrospective study, we could not show
any bene®t of postoperative radiation therapy. One should
note that patients given postoperative radiation therapy had
signi®cantly higher pT-classi®cation, ureteral localisation,
and higher grade tumours (Table 1) compared with non-
irradiated patients. However, no statistically signi®cant dif-
ference was found in terms of local or locoregional control
between patients receiving postoperative radiotherapy and
those not (Table 4), whilst the latter showed a better survival
(Table 3). In their series including 41 patients, Brookland
and Richter [4] reported that local recurrence was less,
although distant failure was about the same with post-
operative radiation therapy (Table 6).
In our series, the rate of distant failures was relatively high
(19%), which was also reported as high as 54% by Maulard-
Durdux and colleagues [7]. For this reason, adjuvant sys-
temic chemotherapy should be investigated because good
objective responses are observed in a palliative setting [20, 21].
We conclude that, in patients with transitional-cell carci-
noma of the renal pelvis and/or ureter, a radical surgical atti-
tude is mandatory; and presence of tumour in the ureter is
associated with a poorer prognosis. Nevertheless, with the
introduction of more sophisticated treatment planning, con-
formal techniques, and intensity modulation, the role of
postoperative radiotherapy remains to be reassessed.
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